BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38644269)

  • 21. [Analysis on efficacy and safety of total neoadjuvant therapy in patients with locally advanced rectal cancer with high risk factors].
    Ouyang GL; Meng WJ; Shu P; Deng XB; Wu B; Jiang D; Zhuang H; Shen YL; Zhou ZG; Wang ZQ; Wang X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Apr; 22(4):349-356. PubMed ID: 31054549
    [No Abstract]   [Full Text] [Related]  

  • 22. Prognostic impact of residual lateral lymph node metastasis after neoadjuvant (chemo)radiotherapy in patients with advanced low rectal cancer.
    Akiyoshi T; Toda S; Tominaga T; Oba K; Tomizawa K; Hanaoka Y; Nagasaki T; Konishi T; Matoba S; Fukunaga Y; Ueno M; Kuroyanagi H
    BJS Open; 2019 Dec; 3(6):822-829. PubMed ID: 31832589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant rectal score is prognostic for survival: A population-based propensity-matched analysis.
    Naffouje SA; Manguso N; Imanirad I; Sahin IH; Xie H; Hoffe S; Frakes J; Sanchez J; Dessureault S; Felder S
    J Surg Oncol; 2022 Dec; 126(7):1219-1231. PubMed ID: 35916542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of platelet-associated biomarkers in rectal cancer patients received neoadjuvant chemoradiation: A retrospective study.
    Wang P; Wang Z; Liu Y; Xie J; Ren Y
    Cancer Radiother; 2021 Apr; 25(2):147-154. PubMed ID: 33423969
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-Adapted Adjuvant Chemotherapy After Concomitant Fluoropyrimidine-Radiotherapy Neoadjuvant Treatment for Patients With Resectable CT3-4 or N+ Rectal Cancer: Five-Year Disease-Free Survival Results of a Single-Center Series.
    Sastre J; Serrano JJ; Fernández C; Ramirez C; Ortega L; García-Paredes B; Corona J; Alfonso R; Córdoba S; Díaz-Rubio E
    Clin Colorectal Cancer; 2016 Jun; 15(2):128-34. PubMed ID: 26385572
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term results of a multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (JACCRO CC-04: SHOGUN Trial).
    Kondo K; Matsusaka S; Ishihara S; Horie H; Uehara K; Oguchi M; Murafushi K; Ueno M; Mizunuma N; Shimbo T; Kato D; Okuda J; Hashiguchi Y; Nakazawa M; Sunami E; Kawai K; Yamashita H; Okada T; Ishikawa Y; Fujii M; Nakajima T
    Radiother Oncol; 2019 May; 134():199-203. PubMed ID: 31005216
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic Impact of the Neoadjuvant Rectal Score as Compared With the Tumor Regression Grade and Yield Pathologic TNM Stage in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy.
    Baek JH; Baek DW; Kang BW; Kim HJ; Park SY; Park JS; Choi GS; Kim JG
    In Vivo; 2020; 34(4):1993-1999. PubMed ID: 32606172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical outcomes of elderly patients receiving neoadjuvant chemoradiation for locally advanced rectal cancer.
    Jiang DM; Raissouni S; Mercer J; Kumar A; Goodwin R; Heng DY; Tang PA; Doll C; MacLean A; Powell E; Price-Hiller J; Monzon J; Cheung WY; Vickers MM
    Ann Oncol; 2015 Oct; 26(10):2102-6. PubMed ID: 26232491
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of efficacy and safety of preoperative Chemoradiotherapy in locally advanced upper and middle/lower rectal cancer.
    Huang MY; Lee HH; Tsai HL; Huang CW; Yeh YS; Ma CJ; Huang CM; Chen CY; Huang JJ; Wang JY
    Radiat Oncol; 2018 Mar; 13(1):53. PubMed ID: 29587797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Short-course radiotherapy with consolidation chemotherapy versus conventionally fractionated long-course chemoradiotherapy for locally advanced rectal cancer: randomized clinical trial.
    Chakrabarti D; Rajan S; Akhtar N; Qayoom S; Gupta S; Verma M; Srivastava K; Kumar V; Bhatt MLB; Gupta R
    Br J Surg; 2021 May; 108(5):511-520. PubMed ID: 33724296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. College of American Pathologists Tumor Regression Grading System for Long-Term Outcome in Patients with Locally Advanced Rectal Cancer.
    Chen HY; Feng LL; Li M; Ju HQ; Ding Y; Lan M; Song SM; Han WD; Yu L; Wei MB; Pang XL; He F; Liu S; Zheng J; Ma Y; Lin CY; Lan P; Huang MJ; Zou YF; Yang ZL; Wang T; Lang JY; Orangio GR; Poylin V; Ajani JA; Wang WH; Wan XB
    Oncologist; 2021 May; 26(5):e780-e793. PubMed ID: 33543577
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of Treatment Adherence With Oncologic Outcomes for Patients With Rectal Cancer: A Post Hoc Analysis of the CAO/ARO/AIO-04 Phase 3 Randomized Clinical Trial.
    Diefenhardt M; Ludmir EB; Hofheinz RD; Ghadimi M; Minsky BD; Rödel C; Fokas E
    JAMA Oncol; 2020 Sep; 6(9):1416-1421. PubMed ID: 32644104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative Adjuvant Treatment Strategy for Locally Advanced Rectal Cancer after Neoadjuvant Treatment.
    Li JY; Huang XZ; Gao P; Chen XW; Song YX; Lv XE; Fu Y; Xiao Q; Wang ZN
    Biomed Res Int; 2021; 2021():8852699. PubMed ID: 34337057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301).
    Miwa K; Oki E; Enomoto M; Ihara K; Ando K; Fujita F; Tominaga M; Mori S; Nakayama G; Shimokawa M; Saeki H; Baba H; Mori M; Akagi Y
    BMC Cancer; 2021 Jan; 21(1):23. PubMed ID: 33402130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. mFOLFOXIRI versus mFOLFOX6 as neoadjuvant chemotherapy in locally advanced rectal cancer: A Propensity Score Matching Analysis.
    Ding M; Zhang J; Hu H; Cai Y; Ling J; Wu Z; Xie X; Li J; Li W; Deng Y
    Clin Colorectal Cancer; 2022 Mar; 21(1):e12-e20. PubMed ID: 34963563
    [TBL] [Abstract][Full Text] [Related]  

  • 36. MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.
    Patel UB; Brown G; Machado I; Santos-Cores J; Pericay C; Ballesteros E; Salud A; Isabel-Gil M; Montagut C; Maurel J; Ramón-Ayuso J; Martin N; Estevan R; Fernandez-Martos C
    Ann Oncol; 2017 Feb; 28(2):344-353. PubMed ID: 28426108
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peripheral blood CD45RO+T cells is a predictor of the effectiveness of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
    Zhai Z; Wang Z; Jin M; Zhang K
    Medicine (Baltimore); 2021 Jun; 100(25):e26214. PubMed ID: 34160385
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Rectum-preserving surgery after consolidation neoadjuvant therapy or totally neoadjuvant therapy for low rectal cancer: a preliminary report].
    Huang Y; Huang SH; Chi P; Wang XJ; Lin HM; Lu XR; Ye DX; Lin Y; Deng Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Mar; 23(3):281-288. PubMed ID: 32192308
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of Duration of Neoadjuvant Radiation on Rectal Cancer Survival: A Real World Multi-center Retrospective Cohort Study.
    Abdel-Rahman O; Kumar A; Kennecke HF; Speers CH; Cheung WY
    Clin Colorectal Cancer; 2018 Mar; 17(1):e21-e28. PubMed ID: 28709877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant Gastric Score: How Response to Neoadjuvant Chemotherapy Affects Overall Survival and Adjuvant Benefit.
    Wehrle CJ; Seavey CN; Chang J; Stackhouse K; Woo K; Augustin T; Joyce D; Simon R; Walsh RM; Naffouje SA
    Ann Surg Oncol; 2023 Nov; 30(12):7240-7250. PubMed ID: 37659978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.